Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Sanofi (1SAN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sanofi €110, price €70.84, upside +55.0%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
S
Broad data
Oct 2, 2026
Sanofi
1SAN · MIClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value €109.83 · Strongly undervalued (+55.0%)
✓Quality 72/100
✓Healthy Growth (revenue 3y +4.8 %/yr)
✓Solidly profitable · 16.0% net margin (TTM)
✓Low debt · generates free cash flow
!Moderate moat 53/100
Watch Sanofi for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range €65.22 – €99.87 · fair‑value band €69.48 – €157.41 · the €70.84 price screens below the €109.83 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Company profile
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Show more
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Stock analysis
Sanofi (1SAN) currently trades at €70.84, while our model-based Fair Value estimate is €109.83, implying the stock looks roughly 35.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €121.84 per share, and 19 of the 26 models we run sit above the €70.84 price.
Bear case: the Earnings-Based group reads lowest at €35.05, and 7 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €69.48 (bear) to €157.41 (bull), the price of €70.84 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Sanofi reported revenue of €46.7B in FY2025 versus €40.6B in FY2022, a compound +4.8%/yr. Reported net income was €7.8B in FY2025, compounding −2.3%/yr from FY2022.
Key figures
Market cap €85.5B · P/E ratio 17.9 · P/S ratio 2.99 · EPS (TTM) €3.96 · Dividend yield 5.3% · Net margin 16.7% · Return on equity 6.6% · Return on assets (EBIT) 7.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 55%, 1SAN screens cheaper than that median.
Fair Value models
Bear €69.48
Fair Value €109.83
Bull €157.41
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (€2.99 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
€65.54
€101.41
€154.52
76
Growth DCF
€67.15
€99.58
€145.07
75
Owner Earnings
€90.80
€139.44
€211.43
73
All 26 models by family
DCF Models
FCF DCF
€65.54
€101.41
€154.52
76
Owner Earnings
€90.80
€139.44
€211.43
73
5Y Revenue Exit
€64.25
€103.81
€153.42
69
5Y EBITDA Exit
€96.06
€161.98
€237.64
71
5Y P/E Exit
€81.08
€134.58
€189.45
67
10Y Revenue Exit
€61.89
€97.77
€144.13
63
10Y EBITDA Exit
€84.16
€137.67
€207.09
65
10Y P/E Exit
€74.69
€118.88
€171.07
61
Earnings-Based
Graham-Dodd
€44.39
€122.80
€161.29
62
Lynch FV
€24.54
€35.05
€45.57
58
PEG = 1.0
€24.54
€35.05
€45.57
55
EPV
€54.82
€64.88
€73.67
71
Dividend Discount
Gordon GGM
€36.61
€76.12
€120.75
63
DDM Multi-Stage
€36.61
€57.60
€79.82
63
Multiples
P/E Multiple
€107.71
€143.61
€179.51
63
P/S Multiple
€83.23
€110.97
€138.72
58
P/B Multiple
€83.23
€110.97
€138.72
55
EV/EBIT
€96.73
€130.80
€164.88
66
EV/EBITDA
€128.50
€173.17
€217.83
67
EV/Revenue
€67.46
€98.73
€130.00
53
Asset-Based
NCAV (Graham)
€29.82
€39.96
€59.63
54
Growth DCF
Growth DCF
€67.15
€99.58
€145.07
75
Rev-Margin DCF
€64.25
€104.15
€148.62
69
Economic Profit
Residual Income
€54.06
€61.08
€77.56
73
ROIC Compounder
€54.82
€67.48
€84.95
69
Growth Earnings
Growth-Adj P/E
€85.29
€121.84
€158.39
65
Notify me when 1SAN reaches fair value
Put 1SAN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
72/100
Of which business quality 69 · Market factors (momentum, volatility) 43
Profitability
46
Margins and returns on capital today
Quality Growth
60
Are margins and returns improving?
Cashflow
65
Earnings quality: real cash, not paper profit
Fin. Strength
73
Balance sheet, leverage, solvency risk
Investment
90
Disciplined investing over empire-building
Low Volatility
88
Calm price path (market factor)
Momentum
32
Price trend over the last 3–12 months (market factor)
52W Momentum
9
Distance to the 52-week high (market factor)
Net Issuance
99
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
73/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+5.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+5.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.6%
Dividend (yield on the price)5.3%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 21%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +0.7% a year for the price and +2.3% for the forecasts.
Forecast 2026 (sales)+0.8%
Forecast 2027 (sales)+6.2%
Projected 2028 (sales)+5.7%
Projected 2029 (sales)+5.2%
Projected 2030 (sales)+4.7%
Watch 1SAN, get fair value alerts →
Recent news
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
- Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
- Why Is Sanofi (ENXTPA:SAN) Reshaping Its Business Around Vaccines And Mature Medicines?
Compare Sanofi with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Context: sector, industry, market
- Is the Energy sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Energy
- Valuation of the Italy market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Amgen Inc AMGN | $421.51 | $463.66 | +10% |
| Gilead Sciences, Inc GILD | $149.05 | $198.77 | +33% |
| Pfizer Inc PFE | $28.12 | $24.87 | −12% |
| Bristol-Myers Squibb Company BMY | $62.40 | $75.96 | +22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Sanofi (1SAN) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of €109.83 versus a price of €70.84, about +55% upside (undervalued).
What is the fair value of 1SAN?
Our model-based fair value for Sanofi is €109.83 (as of Oct 2, 2026), built from audited fundamentals. The current price: €70.84.
What is the quality score of 1SAN?
Sanofi has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sanofi (1SAN)?
Our model-based price target is the fair value of €109.83 (as of Oct 2, 2026) from 26 valuation models. Cautious scenario €69.48, optimistic scenario €157.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Sanofi stock forecast for 2026?
Our models put fair value at €109.83, about +55% upside versus a price of €70.84 (undervalued). Cautious scenario €69.48, optimistic scenario €157.41. The calculation is refreshed regularly with new filings.
What is the revenue of Sanofi (1SAN)?
Sanofi reported trailing-twelve-month revenue of about €47.4B (latest available figure, as of Oct 2, 2026).
Does Sanofi pay a dividend?
Sanofi currently shows a dividend yield of about 5.32% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Sanofi (1SAN)?
For today's price to be fair in a discounted-cash-flow model, Sanofi would have to grow free cash flow by +2.9 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +4.8 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 1SAN use?
Our models discount Sanofi at 10.0 %: a base by market capitalisation (large), damped by beta 0.28, country premium for Italy. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sanofi that is +2.9 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Sanofi (1SAN) delivered so far?
Over the past 3 years revenue at Sanofi grew +4.8 % a year. The price currently implies +2.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sanofi (1SAN) growing?
The median revenue growth in the sector is +9.2 % a year. That is the yardstick for the growth priced into Sanofi (+2.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sanofi (1SAN)?
The free-cash-flow yield on the price is 8.43 %: that much free cash flow Sanofi produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sanofi (1SAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanofi it is €109.83 per share (as of Oct 2, 2026), against a price of €70.84. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sanofi stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 1SAN trades below its calculated fair value: price €70.84, fair value €109.83, a gap of about +55% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1SAN?
No. The price is what the market pays today (€70.84); the fair value is what the company's own numbers justify (€109.83). For Sanofi the two are €38.99 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sanofi worth?
The market values Sanofi at about €85.5B (market capitalisation, as of Oct 2, 2026). Per share that is €70.84; our models calculate a fair value of €109.83 per share.
What do the bullish and bearish scenarios say about 1SAN?
Our models span a range for Sanofi: cautious scenario €69.48, base €109.83, optimistic €157.41 per share (as of Oct 2, 2026, price €70.84). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1SAN?
Sanofi trades at a price-to-earnings ratio of 17.9 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €109.83 is built from several models across several years. Other multiples: PEG 3.7, P/B 1.5, P/S 2.2, EV/EBITDA 8.6.
What is the PEG ratio of 1SAN?
The PEG ratio of Sanofi is 3.67 (P/E divided by earnings growth, as of Oct 2, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Sanofi (1SAN)?
Balance-sheet figures for Sanofi (as of Oct 2, 2026): return on equity 6.6%, debt of 0.20 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is 1SAN from its 52-week high?
Sanofi trades at €70.84, about 17% below its 52-week high of €85.68 and at the low of €70.84 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €109.83 is for.
Which stocks are comparable to Sanofi?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sanofi stock attractive at the current price?
The data as of Oct 2, 2026: price €70.84, calculated fair value €109.83 (+55%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1SAN calculated?
We run Sanofi through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €109.83, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sanofi currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sanofi (1SAN)?
The closing price on Oct 2, 2026 was €70.84. Our model-based fair value is €109.83, about +55% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sanofi right now?
The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range (€69.48 to €157.41) leaves room in how you read the outcome.
Key figures of Sanofi
How large is the market capitalisation of Sanofi (1SAN)?
The market capitalisation of Sanofi is €85.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sanofi (1SAN)?
The price-to-sales ratio of Sanofi is 2.99 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sanofi (1SAN)?
Earnings per share at Sanofi are €3.96 (price ÷ EPS = P/E 17.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sanofi (1SAN)?
The dividend yield of Sanofi is 5.3% (payout 95.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sanofi (1SAN)?
The net margin of Sanofi is 16.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sanofi (1SAN)?
The return on equity (ROE) of Sanofi is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sanofi (1SAN)?
On an EBIT basis the return on assets of Sanofi is 7.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sanofi (1SAN)?
The operating margin of Sanofi is 20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sanofi (1SAN)?
Revenue at Sanofi is growing +6.0% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sanofi (1SAN)?
Earnings per share at Sanofi are growing −11.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sanofi (1SAN) carry?
The net debt of Sanofi is €10.9B (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sanofi in the live analysis
One click puts Sanofi on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.